Stanton, Sasha E.
Gad, Ekram
Ramos, Erik
Corulli, Lauren
Annis, James
Childs, Jennifer
Katayama, Hiroyuki
Hanash, Samir
Marks, Jeffrey
Disis, Mary L.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (KL2TR000421)
U.S. Department of Health & Human Services | National Institutes of Health (T32 CA00951528)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA129517-4, U01CA141539)
American Cancer Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 15 October 2020
Accepted: 8 April 2021
First Online: 11 May 2021
Competing interests
: S.E.S. has previously had research funding from Precigen through her institution (University of Washington). M.L.D. has stock ownership of VentiRX and Epithany. M.L.D. has received grant funding from EMD Serono, VentiRx, Seattle Genetics, and Celgene. S.H., H.K., E.R., E.G., J.A., and L.C. report no competing interests.